Aptorum Group and DiamiR Biosciences Announce Definitive Merger Agreement

In a significant development within the biotechnology sector, Aptorum Group Limited, a clinical-stage biopharmaceutical company, has entered into a definitive merger agreement with DiamiR Biosciences. This strategic move, announced on July 16, 2025, aims to combine Aptorum’s expertise in developing therapeutic assets for infectious diseases and cancers with DiamiR’s innovative blood-based tests for brain health and other diseases.

Merger Details

The merger, which is set to be an all-stock transaction, will see DiamiR Biosciences becoming a wholly-owned subsidiary of Aptorum Group. Despite the structural change, DiamiR will continue to operate under its name, maintaining its identity and focus on its proprietary diagnostic technologies. The combined entity will remain listed on the Nasdaq Stock Market, leveraging DiamiR’s CLIA-licensed, CAP accredited clinical laboratory in New Hampshire.

Strategic Implications

This merger is poised to enhance Aptorum Group’s portfolio by integrating DiamiR’s cutting-edge diagnostic capabilities, particularly in the realm of neurology. Aptorum, which has been publicly traded on Nasdaq since December 18, 2018, has a market capitalization of $6.64 million as of July 14, 2025, with a close price of $0.97. The company’s focus on addressing unmet medical needs in oncology and infectious diseases aligns well with DiamiR’s diagnostic innovations, potentially opening new avenues for therapeutic and diagnostic solutions.

Market Reaction

While specific market reactions to the merger announcement were not detailed in the news, the strategic alignment of Aptorum and DiamiR’s capabilities is expected to be viewed positively by investors interested in the biotechnology sector. The merger could potentially enhance Aptorum’s valuation by expanding its service offerings and strengthening its position in the healthcare industry.

Conclusion

The merger between Aptorum Group Limited and DiamiR Biosciences represents a strategic expansion of Aptorum’s capabilities in the biotechnology sector. By combining therapeutic development with advanced diagnostic technologies, the newly formed entity is well-positioned to address a broader range of unmet medical needs, potentially driving growth and innovation in the healthcare industry.